NCT01110876 2021-08-25
Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM)
M.D. Anderson Cancer Center
Phase 1/2 Terminated
Clinical Trials
7 trialsNCT00335764 2018-07-02
Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00045110 2017-08-17
Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00301418 2016-02-10
Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma
Northwell Health
Phase 1/2 Completed
NCT00124657 2015-12-04
Erlotinib and Radiation Therapy in Treating Young Patients With Newly Diagnosed Glioma
St. Jude Children's Research Hospital
Phase 1/2 Completed
NCT00112736 2015-06-15
Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00101348 2014-06-11
Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed